About Neopharm
Neopharm is a company based in Daejeon (South Korea) founded in 2000. The company has 171 employees. Neopharm offers products and services including Hillo Wave, Atofarm Real Barrier, and Dermabi. Neopharm operates in a competitive market with competitors including Evotec, Crown Bioscience, Alloy Therapeutics, Domainex and NIH, among others.
- Headquarter Daejeon, South Korea
- Employees 171
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website neopharm.co.kr/ko/default.do
- Legal Name Neopharm Co., Ltd.
- Annual Revenue$91.52 M (USD)11.07as on Dec 31, 2025
- Net Profit$19.26 M (USD)20.63as on Dec 31, 2025
- EBITDA$22.07 M (USD)14.87as on Dec 31, 2025
- Employee Count171
Products & Services of Neopharm
Neopharm offers a comprehensive portfolio of products and services, including Hillo Wave, Atofarm Real Barrier, and Dermabi.
Skin booster for dermatological treatments and enhancements.
Dermatology-focused barrier cream for skin protection.
Treatment for skin conditions and daily care routines.
IPO & Listings of Neopharm
Neopharm is a publicly listed company on the KRX with ticker symbol 092730 in South Korea, operating in the Consumer non-durables sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jan 2007
- Listed onKRX: 092730
- Listed entityNeoPharm Co., Ltd.
- Exchange sectorConsumer non-durables
- ISINKR7092730001
- Share price23,150.00 KRW (-4.54% on the day) · 2026-10-08
- Market capitalisation362,095,084,095.00 KRW
- Price to earnings11.8
- EPS (diluted, trailing year)1,959.47 KRW
- Dividend yield3.24%
- Volume (last session)33,859
Financials of Neopharm
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 132.18B KRW | 27.82B KRW | 31.88B KRW |
| 2024 | 119.01B KRW | 23.06B KRW | 27.75B KRW |
| 2023 | 97.10B KRW | 23.21B KRW | 26.93B KRW |
| 2022 | 85.03B KRW | 17.03B KRW | 23.00B KRW |
| 2021 | 87.93B KRW | 17.71B KRW | 23.88B KRW |
Detailed financial statements for Neopharm
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Neopharm
Neopharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evotec, Crown Bioscience, Alloy Therapeutics, Domainex and NIH, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| evotec.com | 1993 | Hamburg, Germany | $25M | 252 | Drug discovery and development services are provided to biopharma sector. | |
| crownbio.com | 2006 | Santa Clara, United States | $85.87M | 18 | Cancer and CVMD drugs are developed using PDX models. | |
| alloytx.com | 2017 | Lexington, United States | $117M | – | Drug discovery services are provided for therapeutic development. | |
| domainex.co.uk | 2001 | Cambridge, United Kingdom | $4.97M | 93 | Drug discovery CRO company for epigenetic research and inflammatory diseases | |
| nih.gov | 1887 | United States | – | – | Drug discovery services are provided to the biopharma sector. | |
| vivabiotech.com | 2006 | Shanghai, China | – | – | Drug discovery and development research services are provided. | |
| catsci.com | 2010 | Cardiff, United Kingdom | $5.89M | 63 | Drug discovery services are provided to pharmaceutical clients worldwide. | |
| qyuns.net | 2015 | Taizhou, China | $66.35M | – | Drug development services are provided to the biopharma sector. | |
| conceptlifesciences.com | 2014 | Manchester, United Kingdom | – | – | International laboratory testing and consultancy in life sciences are offered. | |
| staqpharma.com | 2018 | Denver, United States | $33.52M | 30 | Drug discovery services are provided for pharmaceutical innovation. |
Detailed competitors of Neopharm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Neopharm
The website of Neopharm (neopharm.co.kr) receives about 159.9K visits a month.
- Monthly visits159.9K
▲ 42.2% vs previous month
Websites whose visitors overlap most with Neopharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
neopharmshop.co.kr | neopharmshop.co.kr | 100% | – | #219,811 | – |
zeroid.co.kr | zeroid.co.kr | 86% | – | #599,183 | – |
kcia.or.kr | kcia.or.kr | 81% | – | #223,839 | – |
cosinkorea.com | cosinkorea.com | 71% | – | #486,012 | – |
| torriden.com | 68% | – | #434,483 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Neopharm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Neopharm
Complete news archive for Neopharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Neopharm
10 companies that operate in the same segment as Neopharm (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Neopharm
Neopharm was founded in 2000.
Neopharm is headquartered in Daejeon, South Korea.
Neopharm has 171 employees.
Annual revenue of Neopharm is $91.52M as on Dec 31, 2025.
Neopharm was established in 2000 in Daejeon, South Korea, within the skin care sector. Research on skin science is conducted, and products are developed under brands including Atopalm, Real Barrier, Zeroid, and Derma B. Formulations are created for various skin types, such as dry, oily, and sensitive, to address diverse dermatological needs in the consumer health market.
Neopharm's top competitors include Evotec, Crown Bioscience and NIH.
Neopharm offers Hillo Wave, Atofarm Real Barrier, and Dermabi.
Yes, Neopharm is publicly traded on KRX under the ticker symbol 092730.
Neopharm operates through Neopharm Co., Ltd..
The website of Neopharm receives about 160 thousand visits a month.